(NASDAQ:GBLI), WILMINGTON, Del., March 05, 2026 (GLOBE NEWSWIRE) — Global Indemnity Group, LLC (NASDAQ:GBLI) (“GBLI”) announced that its Board of Directors has approved a distribution payment of $0.35 per common share to be paid on March 30, 2026 to all shareholders of record as of the close of business on March 20, 2026. About Global […]
(NYSE MKT:AEON), IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX(R) (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting,
(NASDAQ:ASLE), Fourth Quarter 2025 Highlights Revenue of $90.9 million versus $94.7 million in the prior year period GAAP net income of $5.4 million versus GAAP net income of $2.7 million in the prior year period Adjusted net income1 of $7.5 million versus adjusted net income of $4.8 million in the prior year period Adjusted EBITDA1
(NASDAQ:NXTC), Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of 2026 BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed
(NASDAQ:MGX), Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company's strategic evolution $160.8 million in cash, cash equivalents and available-for-sale marketable
(NASDAQ:MDGL), CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The
(NASDAQ:AVIR), Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL
(NYSE:COHR), SAXONBURG, Pa., March 05, 2026 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced the launch of Thermadite(TM) 800 Liquid Cold Plates (LCP) for next-generation AI accelerator cooling. Thermadite 800 delivers thermal conductivity of 800W/(mâ‹…K) – approximately twice that of copper – combined with a low coefficient of thermal
(NYSE:TRC), LEBEC, Calif., March 05, 2026 (GLOBE NEWSWIRE) — Tejon Ranch Co., or the Company, (NYSE: TRC), a diversified real estate development and agribusiness company, today announced it will release its fourth quarter and full year 2025 operating and financial results before the market opens on March 19, 2026. In connection with this announcement, the
(NasdaqGM:ULBI), NEWARK, N.Y., March 05, 2026 (GLOBE NEWSWIRE) — Ultralife Corporation (NASDAQ: ULBI) will report its fourth quarter results for the period ending December 31, 2025 before the market opens on Tuesday, March 10, 2026. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on March 10, 2026.